20 Years of RA Data: First-Line Biologic & Targeted Synthetic DMARD Trends
Insight into the Biosimilar Prescribing Habits of Rheumatologists
Higher Risk of Adverse Events When Biologic Infusions Are Done at Home
Injection Pen May Reduce Injection Fear Among RA Patients Taking Etanercept Biosimilar
The Race Is On: Clinical Trials Begin for Agents Biosimilar to Denosumab
Secukinumab Effective Across the Spectrum of Psoriatic Arthritis
When Switching Patients to Biosimilars, Communication & Expert Nurses Reduce the Nocebo Effect
New Clinical Trials for Ustekinumab & Denosumab Biosimilars Begin Recruitment
Health Canada Approves CT-P13 SC for RA; Plus Tofacitinib May Increase Cardiac & Cancer Risks
- 1
- 2
- 3
- …
- 34
- Next Page »